Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Gut

Retrieve available abstracts of 25 articles:
HTML format

Single Articles

    October 2022
  1. LANG-MELI J, Neumann-Haefelin C
    Prophylactic vaccination against hepatitis D virus superinfection: from fiction to reality?
    Gut. 2022 Oct 19. pii: gutjnl-2022-328381. doi: 10.1136/gutjnl-2022-328381.

    September 2022
  2. VENTURA-COTS M, Argemi J, Jones PD, Lackner C, et al
    Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.
    Gut. 2022;71:1856-1866.
    PubMed     Abstract available

    August 2022
  3. BURM R, Maravelia P, Ahlen G, Ciesek S, et al
    Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
    Gut. 2022 Aug 17. pii: gutjnl-2022-327216. doi: 10.1136/gutjnl-2022-327216.
    PubMed     Abstract available

  4. ALZUA GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, et al
    Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
    Gut. 2022 Aug 2. pii: gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323.
    PubMed     Abstract available

    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.

    July 2022
  6. WIGGINS BG, Pallett LJ, Li X, Davies SP, et al
    The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations.
    Gut. 2022;71:1399-1411.
    PubMed     Abstract available

    May 2022
  7. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available

  8. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.

    February 2022
  9. ALLWEISS L, Giersch K, Pirosu A, Volz T, et al
    Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
    Gut. 2022;71:372-381.
    PubMed     Abstract available

    January 2022
  10. LI J, Liang X, Jiang J, Yang L, et al
    PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
    Gut. 2022;71:163-175.
    PubMed     Abstract available

    October 2021
  11. ALIABADI E, Urbanek-Quaing M, Maasoumy B, Bremer B, et al
    Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection.
    Gut. 2021 Oct 26. pii: gutjnl-2021-324646. doi: 10.1136/gutjnl-2021-324646.
    PubMed     Abstract available

  12. HSU YC, Tseng CH, Su TH, Kao JH, et al
    Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities.
    Gut. 2021 Oct 20. pii: gutjnl-2021-326232. doi: 10.1136/gutjnl-2021-326232.

  13. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available

    September 2021
  14. HALL SAL, Vogrin S, Wawryk O, Burns GS, et al
    Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
    Gut. 2021 Sep 7. pii: gutjnl-2020-323979. doi: 10.1136/gutjnl-2020-323979.
    PubMed     Abstract available

    June 2021
  15. URBAN S, Neumann-Haefelin C, Lampertico P
    Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
    PubMed     Abstract available

    May 2021
  16. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available

  17. JINDAL A, Vyas A, Dubey G
    Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
    Gut. 2021 May 5. pii: gutjnl-2021-324967. doi: 10.1136/gutjnl-2021-324967.

    April 2021
  18. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    PubMed     Abstract available

    March 2021
  19. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.

  20. LI J, Li J, Chen S, Yuan Q, et al
    Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C.
    Gut. 2021;70:575-584.
    PubMed     Abstract available

    February 2021
  21. WIJAYA RS, Read SA, Truong NR, Han S, et al
    HBV vaccination and HBV infection induces HBV-specific natural killer cell memory.
    Gut. 2021;70:357-369.
    PubMed     Abstract available

    December 2020
  22. KIM MA, Kim SU, Sinn DH, Jang JW, et al
    Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Gut. 2020;69:2214-2222.
    PubMed     Abstract available

    October 2020
  23. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available

    September 2020
  24. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available

    March 2020
  25. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.